The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Insights into evolving mortality trends in multiple myeloma: findings from a SEER analysis
In this video, Shahzad Raza, MD, Cleveland Clinic, Cleveland, OH, briefly discusses an analysis that used the SEER database to investigate the evolving mortality trends in multiple myeloma (MM). Dr Raza highlights that patients who survive beyond three years may now succumb to cardiovascular and infectious diseases rather than multiple myeloma itself, underscoring the need for robust survivorship programs to address the complex medical issues faced by patients living longer with the disease. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
You know that the SEER analysis, we have the largest database in history, where we have a lot of patients, where we can predict how they are going to do, what is their overall survival. So what we did here, we actually divided the survival analysis into multiple segments: pre-novel era, novel era, and then, you know, modern era, and then we’re trying to predict who are the people who have done really good in terms of survival...
You know that the SEER analysis, we have the largest database in history, where we have a lot of patients, where we can predict how they are going to do, what is their overall survival. So what we did here, we actually divided the survival analysis into multiple segments: pre-novel era, novel era, and then, you know, modern era, and then we’re trying to predict who are the people who have done really good in terms of survival. What is striking number one, is that we are improving the survival in multiple myeloma after 2015, so that’s something very exciting. But what we’re also learning is that those who pass their three-year timeline, their mortality is not because of multiple myeloma, that is happening because of cardiovascular and infectious diseases, so the way people are living longer, they have a different type of complexities and different types of medical problems that we are seeing. So I think this data does tell us that we really need to have a robust survivorship program for those patients who are living longer with multiple myeloma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
